Myelodysplastic syndromes (MDS) are a type of rare and heterogeneous hematological malignancy, and immune dysregulation plays a major role in the development of this disease and progression to acute myeloid leukemia (AML). Several novel targets are being explored in this field with the aim of increasing treatment options for patients and improving response to therapies.

In this exclusive podcast, you will hear from leading experts Uwe Platzbecker, MD, Leipzig University Hospital, Leipzig, Germany, Alan List, MD, Precision BioSciences, Durham, NC, David Sallman, MD, Moffitt Cancer Center, Tampa, FL, and Daniel Starczynowski, PhD, Cincinnati Children’s Hospital, Cincinnati, OH, as they discuss immune dysregulation and targeting in MDS. This discussion took place at the 1st International Workshop on Myelodysplastic Syndromes (iwMDS) held in Miami, FL.